Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Moderna

We still need a vaccine patent waiver, but not the one on offer at the World Trade Organization meeting

In mid-June, the World Trade Organization (WTO) will meet to finish negotiations to waive certain sections of the agreement on Trade Related Intellectual Property Rights (TRIPS). However, it is not the TRIPS waiver originally proposed 18 months ago by member states South Africa and India, which would have allowed countries…

The Conversation

NOT REAL NEWS: A look at what didn't happen this week

Social media users shared a range of false claims this week

The Independent UK

Covid vaccines for the under-fives - what parents need to know

Children under five represent the only age group yet to have a vaccine approved for use

Wales Online

From analysis to the latest developments in health,
read the most diverse news in one place.

Pfizer Seeks FDA Approval For Three Covid Vaccine Doses For Children Below Five

Partners Pfizer, Inc (NYSE:PFE) and BioNTech SE (NASDAQ:BNTX) urged the FDA to authorize three vaccine doses for children below five, the Wall Street Journal reports. The companies previously asserted that three doses of the shot were 80% effective at preventing symptomatic Covid-19 with robust immune response in children between six months to five years. After mixed results…

Benzinga

Japan study shows women more likely to get skin rash from Moderna shot

A study in Japan found that women were significantly more likely than men to develop rash-like side effects after a first dose of Moderna Inc's COVID-19 vaccine.

Reuters

Check Out What Whales Are Doing With MRNA

Someone with a lot of money to spend has taken a bullish stance on Moderna (NASDAQ:MRNA). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga.

Benzinga

COVID vaccines for children under five: what parents need to know

Pfizer’s COVID-19 vaccine became available for children aged five to 11 in the UK in April 2022. Those aged 12 and up had already been eligible since 2021.

The Conversation

Read news from The Economist, FT, and more,
with one subscription

Planning a holiday? What’s the COVID situation in Bali, Fiji, NZ and the UK?

Here are a few general tips for a safer and enjoyable holiday, and a quick look at the COVID situation in four popular holiday destinations.

The New Daily

CanSino's Covid Vaccine Gets WHO Nod. But Is It Too Little, Too Late?

Key Takeaways: CanSino’s Covid-19 vaccine Convidecia will be admitted to the global Covax program following its approval by the WHO The approval could have limited benefits for the company as the pandemic fades and other products are widely available By Jony Ho

Benzinga

How important is the COVID-19 booster shot for 5-to-11-year-olds? 5 questions answered

COVID-19 case numbers are rising again in the U.S. – including among children. In mid-May 2022, the Food and Drug Administration authorized a booster shot of the COVID-19 vaccine for U.S. children ages 5 to 11, and the Centers for Disease Control and Prevention followed by recommending a booster shot…

The Conversation

Time 100 Most Influential List Includes 10 Connected To Public Companies Such As Tim Cook, Andy Jassy And Joe Rogan

The annual Time 100 Most Influential People list for 2022 contains names such as U.S. President Joe Biden, Ukrainian President Volodymyr Zelenskyy and Chinese President Xi Jinping. The list also has several CEOs and names connected to public companies.

Benzinga

Moderna Testing Potential Monkeypox Vaccines

Moderna Inc is testing potential vaccines against monkeypox in pre-clinical trials as the disease spreads in the United States and Europe. The World Health Organization said on Tuesday there have been 131 confirmed monkeypox cases and 106 further suspected cases since the first was reported on May 7 outside the…

Asharq Al-Awsat

Peering Into Moderna's Recent Short Interest

Moderna's (NASDAQ:MRNA) short percent of float has fallen 3.7% since its last report. The company recently reported that it has 15.43 million shares sold short, which is 4.43% of all regular shares that are available for trading.

Benzinga

What happened to the AstraZeneca vaccine? How blood clot scares tarnished its reputation

While the AZ./Oxford vaccine has all but vanished from richer countries, it has continued to be rolled out elsewhere

Wales Online

Get all your
news in one place.

100's of premium titles.
One news app.

The Independent UK

China's bet on homegrown mRNA vaccines holds back nation

China is trying to navigate its biggest coronavirus outbreak without a tool it could have adopted many months ago, the kind of vaccines that have proven to offer the best protection against the worst outcomes from COVID-19

Benzinga

Here's How Much You Would Have Made Owning Moderna Stock In The Last 5 Years

Moderna (NASDAQ:MRNA) has outperformed the market over the past 5 years by 102.55% on an annualized basis producing an average annual return of 112.95%. Currently, Moderna has a market capitalization of $54.60 billion.

The Independent UK

What's next for COVID-19 vaccines for youngest US children

Parents hoping to get their youngest children vaccinated against COVID-19 have some encouraging news

Benzinga

Looking At Moderna's Recent Whale Trades

Get all your
news in one place.

100's of premium titles.
One news app.

The Independent UK

Pfizer says 3 COVID shots protect children under 5

Pfizer says three small doses of its COVID-19 vaccine protect kids under 5 and that it plans to give the data to U.S. regulators later this week

Benzinga

Moderna Soars Following FDA Comments On COVID-19 Vaccine For Kids Under 5: What's Next?

Moderna, Inc (NASDAQ: MRNA) was spiking higher on Thursday, holding up better than the general markets, which saw the S&P 500 rally over 1% off the open before giving it all back.

Benzinga

The Daily Biotech Pulse: Pfizer/BioNTech's COVID-19 Booster For Kids, Moderna Starts First African Trial Of mRNA HIV Vaccine, Tonix Extends COVID-19 Antiviral Research Pact

Here's a roundup of top developments in the biotech space over the last 24 hours.

Benzinga

Morning Brief: Top Financial Stories Dominating on Wednesday, May 18

CNBC Toyota Looks To Develop Hydrogen Mobility In Europe

Benzinga

Moderna's Chairman Defends Executive Hiring Process After Firing New CFO In Just One Day

Moderna Inc’s (NASDAQ: MRNA) chairman comes forward with a determined defense of the board’s executive hiring process after being forced to fire its new chief financial officer just a day after taking charge.

The Hindu

India’s ‘other’ COVID vaccines: The status of under-trial, approved and unused jabs

While Covishield and Covaxin lead the Covid-19 vaccination effort in India, other vaccines, too, are under development or remain unused after approval from the Centre

AAP

Vic institute to tackle neglected diseases

Victoria's Burnet Institute has partnered with Moderna to develop new vaccines for diseases such as malaria and hepatitis C.

1 … 24 25 26 27

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

World Health Organization

915 stories

Read news from The Economist, FT, and more,
with one subscription

Topics

Intellectual Property

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.